Category: Education

We are thrilled that after two years of endless campaigning by many people, Enhertu has been recommended by NICE for use on the NHS in England for people living with HER2-low secondary (metastatic) breast cancer. This is a significant day for women and men living across England who have been waiting for Enhertu to become available.

The Scottish Medicines Consortium (SMC) has accepted two new targeted therapies for NHS Scotland: Elacestrant (Korserdu®) and Capivasertib (Truqap®). This decision represents a major milestone for our community, offering much-needed targeted options for people living with hormone receptor-positive, HER2-negative advanced breast cancer.

Dear Secretary of State, Congratulations on your appointment as Secretary of State for Health and Social Care. We’d like to ask for your urgent support to ensure the life-extending metastatic breast cancer treatment, Enhertu, is made available on the NHS.

At Make 2nds Count, our goal is to ensure that every person living with secondary (metastatic) breast cancer across the UK has equitable access to life-extending treatments. Today, in partnership with Breast Cancer Now and METUPUK, we have published an open letter to the newly appointed Chair of the Scottish Medicines Consortium (SMC), Dr Robert Peel.

We are deeply saddened to share the news that the Scottish Medicines Consortium (SMC) has decided not to approve Elacestrant for use on the NHS in Scotland. Elacestrant is a targeted treatment for postmenopausal women and men with hormone receptor positive, HER2 negative, secondary breast cancer who have an ESR1 mutation, with disease progression after hormone therapy, including a CDK 4/6 inhibitor.